In severe COVID-19, an oversized dysregulation of the inflammation-immunosuppression balance, evaluated by biomarkers such as serum interleukin 6 (IL-6), monocyte human histocompatibility leukocyte antigen expression rate mHLA-DR, and the IL-6:mHLA-DR ratio have been associated with worst outcome, including C-AKI and mortality [23, 24]. This evidence concerns the gene IL6 and COVID-19.